C o m p a n y U p d a t e 公司基本资讯 产业别 农林牧渔 A 股价(2024/8/19) 18.70 深证成指(2024/8/19) 8356.90 股价 12 个月高/低 27.15/17.92 总发行股数(百万) 294.11 A 股数(百万) 294.11 A 市值(亿元) 55.00 主要股东 烟台中幸生物 科技有限公司 (24.86%) 每股净值(元) 7.69 股价/账面净值 2.43 一个月 三个月 一年 股价涨跌(%) -3.6 -17.9 -22.2 近期评等 出刊日期 2024-04-23 2023-10-30 2023-08-04 2023-06-26 前日收盘 24.27 22.55 25.26 23.83 评等 买进 买进 买进 区间操作 产品组合 宠物零食 58.06% 宠物罐头 15.43% 宠物主粮 21.56% 宠物用品 4.95% 阿 2024 年 08 月 20 日 顾向君 H70420@capitalcom.tw 目标价(元) 22 机构投资者占流通 A 股比例 基金 一般法人 股价相对大盘走势 中宠股份(002891.SZ) BUY 买进 Q ...

C o m p a n y U p d a t e 吉祥航空(603885.SH) 买进（Buy） 公司基本信息 | --- | --- | --- | --- | |---------------------|--------|--------|-------------| | 产业别 | | | 交通运输 | | A 股价(2024/8/15) | | | 11.13 | | 上证指数(2024/8/15) | | | 2877.36 | | 股价 12 个月高/低 | | | 17.31/10.47 | | 总发行股数(百万) | | | 2214.01 | | A 股数(百万) | | | 2214.01 | | A 市值(亿元) | | | 246.42 | | 主要股东 | | | 上海均瑶(集 | | | | 团) | 有限公司 | | | | | (46.11%) | | 每股净值(元) | | | 3.82 | | 股价/账面净值 | | | 2.92 | | | 一个月 | 三个月 | 一年 | | 股价涨跌(%) | | | | 近期评等 出刊日期 前日收盘 评等 产品组合 | --- ...

C o m p a n y U p d a t e 2024 年 08 月 13 日 费倩然 H70507@capital.com.tw 目标价(元) 25.5 公司基本资讯 | --- | --- | |---------------------|----------------| | 产业别 | 化工 | | A 股价(2024/8/12) | 19.66 | | 上证指数(2024/8/12) | 2858.20 | | 股价 12 个月高/低 | 22/13.44 | | 总发行股数(百万) | 1834.33 | | A 股数(百万) | 1834.33 | | A 市值(亿元) | 360.63 | | 主要股东 | 云天化集团有 | | | 限责任公司 | | | (38.12%) | | 每股净值(元) | 10.83 | | 股价/账面净值 | 1.81 | | | 三个月 一年 | | 股价涨跌(%) | -6.5 -3.8 13.3 | 近期评等 | --- | --- | --- | |------------|----------|-------| | 出刊日期 | 前日收盘 | 评 ...

C o m p a n y U p d a t e 2024 年 08 月 13 日 费倩然 H70507@capital.com.tw 目标价(元) 25.5 公司基本资讯 | --- | --- | |---------------------|----------------| | 产业别 | 化工 | | A 股价(2024/8/12) | 19.66 | | 上证指数(2024/8/12) | 2858.20 | | 股价 12 个月高/低 | 22/13.44 | | 总发行股数(百万) | 1834.33 | | A 股数(百万) | 1834.33 | | A 市值(亿元) | 360.63 | | 主要股东 | 云天化集团有 | | | 限责任公司 | | | (38.12%) | | 每股净值(元) | 10.83 | | 股价/账面净值 | 1.81 | | | 三个月 一年 | | 股价涨跌(%) | -6.5 -3.8 13.3 | 近期评等 | --- | --- | --- | |------------|----------|-------| | 出刊日期 | 前日收盘 | 评 ...

C o m p a n y U p d a t e 2024 年 08 月 13 日 费倩然 H70507@capital.com.tw 目标价(元) 20 公司基本资讯 | --- | --- | |---------------------|--------------| | 产业别 | 化工 | | A 股价(2024/8/12) | 15.35 | | 上证指数(2024/8/12) | 2858.20 | | 股价 12 个月高/低 | 17.63/12.62 | | 总发行股数(百万) | 7333.36 | | A 股数(百万) | 7333.36 | | A 市值(亿元) | 1125.67 | | 主要股东 | 宁夏宝丰集团 | | | 有限公司 | | | (35.65%) | | 每股净值(元) | 5.46 | | 股价/账面净值 | 2.81 | | | 三个月 一年 | | 股价涨跌(%) | | 近期评等 | --- | --- | --- | |------------|----------|-------| | 出刊日期 | 前日收盘 | 评等 | | 2024.05.30 ...

C o m p a n y U p d a t e 2024 年 08 月 13 日 费倩然 H70507@capital.com.tw 目标价(元) 20 公司基本资讯 | --- | --- | |---------------------|--------------| | 产业别 | 化工 | | A 股价(2024/8/12) | 15.35 | | 上证指数(2024/8/12) | 2858.20 | | 股价 12 个月高/低 | 17.63/12.62 | | 总发行股数(百万) | 7333.36 | | A 股数(百万) | 7333.36 | | A 市值(亿元) | 1125.67 | | 主要股东 | 宁夏宝丰集团 | | | 有限公司 | | | (35.65%) | | 每股净值(元) | 5.46 | | 股价/账面净值 | 2.81 | | | 三个月 一年 | | 股价涨跌(%) | | 近期评等 | --- | --- | --- | |------------|----------|-------| | 出刊日期 | 前日收盘 | 评等 | | 2024.05.30 ...

C o m p a n y U p d a t e 锦江酒店(600754.SH/900934.SH) BUY 买进 公司基本资讯 | --- | --- | --- | |--------------------|--------|----------------| | 产业别 | | 休闲服务 | | A 股价(2024/8/9) | | 23.68 | | 上证指数(2024/8/9) | | 2862.19 | | 股价 12 个月高/低 | | 47.06/21.01 | | 总发行股数(百万) | | 1070.04 | | A 股数(百万) | | 914.04 | | A 市值(亿元) | | 216.45 | | 主要股东 | | 上海锦江资本有 | | | 限公司 | (45.05%) | | 每股净值(元) | | 15.28 | | 股价/账面净值 | | 1.55 | | | 三个月 | 一年 | | 股价涨跌(%) | | | | --- | |------------| | 近期评等 | | 出刊日期 | | 2024-07-15 | | 2023-12-27 | | 2023- ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 1674 RMB per share [1][9]. Core Insights - The company achieved a total revenue of 68.57 billion RMB in H1 2024, representing a year-on-year increase of 15.7%. The revenue from series liquor reached 13.15 billion RMB, up 30.5% year-on-year. In Q2, the revenue from Moutai liquor was 28.86 billion RMB, a 12.9% increase year-on-year, while series liquor revenue was 7.21 billion RMB, up 42.5% year-on-year [1]. - The company has announced a cash dividend plan for 2024-2026, aiming for a payout ratio of no less than 75% annually, with expected dividend yields of 3.6%, 4.2%, and 4.6% for the respective years [6]. - The net profit forecast for 2024-2026 has been adjusted to 87 billion RMB, 99.4 billion RMB, and 110.73 billion RMB, reflecting year-on-year growth rates of 16.4%, 14.3%, and 11.4% respectively [6]. Financial Summary - The company reported a net profit of 52.46 billion RMB in 2023, with a year-on-year increase of 12.34%. The earnings per share (EPS) for 2023 was 41.76 RMB, with a projected EPS of 69.25 RMB for 2024 [2][3]. - The operating income is projected to grow from 150.56 billion RMB in 2023 to 175.77 billion RMB in 2024, with a steady increase expected through 2026 [3]. - The company’s gross margin remained stable in H1, while the expense ratio for the first half was 6.8%, benefiting from improved management efficiency [11]. Product Composition - The product mix consists of 83.9% Moutai liquor and 16.1% series liquor, indicating a strong reliance on the flagship product [4]. Market Performance - The stock price as of August 8, 2024, was 1430.69 RMB, with a market capitalization of approximately 179.72 billion RMB [14]. The stock has experienced a decline of 21.8% over the past year [14].

C o m p a n y U p d a t e 安琪酵母(600298.SH) BUY 买进 公司基本资讯 | --- | --- | --- | --- | |--------------------|--------|--------|--------------| | 产业别 | | | 农林牧渔 | | A 股价(2024/8/7) | | | 29.61 | | 上证指数(2024/8/7) | | | 2869.83 | | 股价 12 个月高/低 | | | 36.61/27.22 | | 总发行股数(百万) | | | 868.67 | | A 股数(百万) | | | 865.97 | | A 市值(亿元) | | | 256.41 | | 主要股东 | | | 湖北安琪生物 | | | | | 集团有限公司 | | | | | (38.07%) | | 每股净值(元) | | | 11.72 | | 股价/账面净值 | | | 2.53 | | | 一个月 | 三个月 | 一年 | | 股价涨跌(%) | | | | | --- | |------------| | 近期评等 | | ...

Investment Rating - The investment rating for the company is "Buy" [4][5]. Core Insights - The company achieved a revenue of 2.76 billion RMB in the first half of 2024, representing a year-over-year increase of 15.1%, with a net profit of 630 million RMB, also up by 15.5% year-over-year [4]. - The anesthetics segment showed significant growth, with revenue reaching 1.52 billion RMB, a year-over-year increase of 20.0%, driven by the increasing sales of sufentanil and alfentanil [4]. - The company has a robust pipeline with over 70 projects in development, including more than 20 innovative drugs, which is expected to support long-term growth [4]. Summary by Sections Company Overview - The company operates in the pharmaceutical and biotechnology industry, with a current A-share price of 24.02 RMB as of July 30, 2024, and a target price of 28 RMB [2][4]. - The company has a market capitalization of 21.18 billion RMB and a total share count of approximately 1,007.59 million shares [2]. Financial Performance - In Q2 2024, the company reported a revenue of 1.41 billion RMB, with a net profit of 360 million RMB, reflecting a year-over-year increase of 14.6% [4]. - The overall gross margin for Q2 was 74.2%, with a slight increase of 0.1 percentage points year-over-year [4]. Future Projections - The company is expected to achieve net profits of 1.26 billion RMB, 1.51 billion RMB, and 1.80 billion RMB for the years 2024, 2025, and 2026, respectively, with year-over-year growth rates of 21.0%, 20.0%, and 19.5% [5][6]. - The estimated earnings per share (EPS) for the same years are projected to be 1.25 RMB, 1.49 RMB, and 1.79 RMB, with corresponding price-to-earnings (P/E) ratios of 19, 16, and 13 [5][6].